To improve patients’ quality of lives through the discovery, development and commercialization of innovative cancer and viral treatments with proven clinical benefits.

BioApex is a private biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders, including cancer and viral diseases. We see ourselves first and foremost as a “research tank.”

Our goals are to (1) research and develop a broad portfolio of low molecular weight compounds that are novel and prove highly effective in fighting certain cancers and virus-induced cancerous cells, (2) back our compounds with comprehensive patents, (3) partner with industry leaders in the cost-intensive stages of drug development and marketing, and (4) become a profitable and recognized leader in the areas of our focus and vital partner for “big pharma.”

There are three key elements to our business strategy:

1. Focus on developing novel, cell cycle-based therapies for the treatment of cancer and other serious disease indications.

Focus on a broad research and development of a new derivatives of natural compounds with anti-viral, anti-proliferative, anti-angiogenic and anti-senescence properties, the molecular mechanisms of their action and the potential combinatory therapies allows BioApex to minimize risk of the developmental programmes.

2. Develop anticancer drug candidates in all phases of the cell cycle and multiple compounds for particular cell cycle targets.

Targeting a broad development program focused on multiple phases of the cell cycle allows BioApex to minimize risk while maximizing the potential for success and develop products that are complementary to one another.

3. Enter into partnering arrangements selectively, while developing our own sales and marketing capability for niche markets.

Selectively, BioApex retains all licensing rights to the compounds associated with the current preclinical-stage drug programs. To optimize returns, we intend to license our compounds to pharmaceutical companies with research and development focus and established sales and marketing channels in our areas of interest; occasionally, we may market the products ourselves in selected niche markets. Generally, we intend to develop compounds through the Phase 1 proof-of-efficacy stage before seeking a partner. We may enter into partnership arrangements earlier in connection with drug programs outside the current oncology core competency.